Will the FDA provide a clear regulatory pathway for ANKTIVA in NSCLC by December 31, 2026?
Current Prediction
Prediction History
Baseline 0.38 reflected management's stated intent to pursue US NSCLC discussions in 2026. Absent Q1 progress and with the warning letter overhang, timing pressure on H2 2026 increases. Nudged down to 0.32.
Why This Question Matters
US NSCLC represents the largest potential expansion market for ANKTIVA. The Regulatory Reader noted discussions planned for 2026 but no formal pathway established. FDA clarity on NSCLC would materially de-risk the multi-indication thesis. Absence of progress would narrow the growth narrative to bladder cancer only.
Prediction Distribution
Individual Predictions(9 runs)
No Q1 update on US NSCLC pathway. Management bandwidth is focused on BCG-naive sBLA (higher-value near-term catalyst). The FDA warning letter creates a cooler regulatory tone that could delay a meeting or pathway disclosure. Probability lowered modestly from baseline 0.38.
The resolution criteria require a formal disclosure by year-end (IND, sNDA, BLA, or published meeting minutes). Without Q1 progress, the runway for H2 2026 action is narrowing. Saudi approval is helpful precedent but does not translate to US pathway.
Company's multi-indication ambitions remain real. An FDA Type B or C meeting on NSCLC pathway could be disclosed later in 2026. But the warning letter and focus on bladder expansion argue for slippage into 2027.
Baseline 0.38 was predicated on 'discussions planned for 2026.' No Q1 progress modestly reduces probability. Warning letter adds a small additional drag.
The resolution criteria are specific (IND acceptance, sNDA, BLA, or meeting minutes). Less formal pathway communications may occur but wouldn't resolve YES. Base rate for meeting disclosure of this specificity in a given calendar year: ~30%.
Probability shifts modestly lower with Q1 no-update, offset partially by possibility the company accelerates NSCLC discussions post-BCG-naive sBLA submission if that goes well.
No Q1 progress. Warning letter headwind. Probability ~32%.
Specific criteria + competing priorities = moderate-low probability.
Still possible but less likely than baseline.
Resolution Criteria
Resolves YES if ImmunityBio publicly discloses FDA acceptance of an IND, sNDA, BLA submission, or published meeting minutes confirming a clear pathway (accelerated approval, breakthrough therapy designation, etc.) for ANKTIVA in NSCLC by December 31, 2026.
Resolution Source
ImmunityBio press releases, 8-K filings, or FDA meeting minutes
Source Trigger
US FDA pathway decision for NSCLC indication
Full multi-lens equity analysis